CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

CRISPR Therapeutics (NasdaqGM:CRSP) recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction.

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Avantax Advisory Services Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...

Harbour Investments Inc. reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.9% during the 4th ...

Crispr Therapeutics (CRSP) announced that its COO, Julianne Bruno, will be stepping down from the company to pursue external opportunities, ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

In this article, we are going to look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market conditions, ...

CRISPR Therapeutics (NASDAQ:CRSP) said on Wednesday that its Chief Operating Officer, Julianne Bruno, will be stepping down to pursue external opportunities, effective as of April 11, 2025.